GILD Stock Lost 4%, Gilead Sciences Disputes Report on Poor Results of Remdesivir Trial

Coinspeaker
GILD Stock Lost 4%, Gilead Sciences Disputes Report on Poor Results of Remdesivir Trial

WHO accidentally posted a draft summary of remdesivir trial studies. As soon as the organization realized the mistake, it deleted the post. But Gilead (GILD) stock plunged.

GILD Stock Lost 4%, Gilead Sciences Disputes Report on Poor Results of Remdesivir Trial

Coinspeaker

32 total views, 1 views today

Author: toutiao